DiversiTEA Corner, Fall 2022

A woman in a patterned dress smiling and standing in front of trees and stones.
October 17, 2022
Read the fall 2022 edition of DiversiTEA Corner, the newsletter about inclusion, diversity, equity and accessibility at the UT College of Pharmacy. This semester’s topics include New Student Orientation, transgender and gender-nonconforming healthcare, National Hispanic Heritage Month, patients with Sickle Cell Disease, and many more.

UT Pharmacy Supports Grad Students with Building Our Own Talent (BOOT) Program

Two people smiling.
September 8, 2022
This year, college welcomes Daniel San Miguel and Adriana Vargus through the BOOT program, providing a generous 12-month stipend plus paid tuition for the first academic year in order to to increase the recruitment, retention and preparation of trainees from diverse backgrounds.

Summer Programs of Innovation and Diversity

LEADER/PEPP Program participants and leaders sitting together at an outdoor table for lunch.
September 6, 2022
This summer, the office of Diversity, Equity, Accessibility, and Inclusion (DEAI), hosted two intensive summer research programs: Project Engage Pharmacy Program (PEPP) Camp and the Leadership Through Engagement For the Advancement of Diverse Educational Research (LEADER) Program.

Pharmacists: The Most Accessible Healthcare Provider, Unless You Have a Substance Use Disorder

White pill bottle with white pills on a black background.
August 23, 2022
P4 students, Megan Yeung, Kami Johnston and Morgan Murchison co-author a peer-reviewed blog in Pulses encouraging educators to adapt to reflect the specific needs of people who use drugs and patients with substance use disorders. This blog also highlights UT Pharmacy as a U.S. leader in substance use disorder and harm reduction education for Pharm.D. students.

Fewer Than Half of U.S. Pharmacies Carry One of the Most Effective Drugs for Opioid Abuse

A pharmacist holding a box of medication.
June 13, 2022
Tara Law from Time writes about how few pharmacies carry buprenorphine, a life-saving drug to help treat opioid use disorder (OUD). Lucas Hill, Pharm.D., BCACP, director of the college's Pharmacy Addictions Research & Medicine (PhARM) program, offers his insight on the issue, and how the DEA's crackdown of the drug puts OUD patients at risk.

DiversiTEA Corner, Spring 2022

A woman smiling.
May 16, 2022
Read the spring 2022 edition of DiversiTEA Corner, the newsletter about inclusion, diversity, equity and accessibility at the UT College of Pharmacy. This semester’s topics include the college's Dr. Carolyn Brown DEAI Champion Award recipients, a message from Pharmacy Council's DEAI chair, a university three-part series on midwives hosted by UT Pharmacy, our newest member of the DEAI team, and many more.

UT Pharmacy Earns Highest Residency Match Rate in Texas

#1 Residency Match Placement in Texas
April 19, 2022
Pharmacy schools across the country completed their 2022 Phase I and Phase II residency matches for new or upcoming graduates of their Doctor of Pharmacy (Pharm.D.) programs. The University of Texas at Austin College of Pharmacy placed in the top ten of all pharmacy schools in the nation, and number one in Texas.

Commencement 2022

Three woman in doctorate regalia holding diplomas.
March 30, 2022
The College of Pharmacy's Convocation Ceremony will be Friday, May 20, 2022. Find more information on the college's Commencement 2022 page.

Recipients of the Dr. Carolyn Brown DEAI Champion Award

Three people smiling.
March 2, 2022
These DEAI Champions have demonstrated exceptional efforts and continue to make significant contributions to creating a more diverse, equitable, accessible and inclusive culture within the college and beyond through their excellent service, teaching, research and/or academic endeavors.

Opioid Use Disorder Paper Earns ACCP Award

A box of naloxone vials.
October 8, 2021
A paper from UT College of Pharmacy researchers was awarded the 2021 Outstanding Paper of the Year from the American College of Clinical Pharmacy (ACCP) Ambulatory Care Practice Research Network. The paper investigates the availability of buprenorphine and naloxone in Texas to treat opioid use disorder.